



Referral Support Service

Paediatrics

PA06 Constipation

Definition

The inability to pass stools regularly OR empty the bowels completely.

Paediatric Normal Values (adapted from APLS)					
Age	Resp Rate	Heart Rate	Systolic BP		
Neonate <4w	40-60	120-160	>60		
Infant <1 y	30-40	110-160	70-90		
Toddler 1-2 yrs	25-35	100-150	75-95		
2-5 yrs	25-30	95-140	85-100		

Exclude Red Flag Symptoms

- Constipation in neonates (<28d)
- Delay in passing meconium (>48h in term infant)
- Abnormal appearance of anus (patency, anterior position, fistula, fissures, bruising)
- Ribbon like stools (with presence of blood or mucus)
- Abnormal neurological examination (lower limbs particularly)
- Deformity in the lower limbs (talipes, contractures)
- Abdominal distension with vomiting (urgent referral)
- Abnormal appearance of spine or sacral region (discoloured skin, hairy patch, sacral dimple, asymmetry of the gluteal muscles
- Previous necrotising enterocolitis in ex-preterm infants

High risk of chronicity

- ASD
- Cerebral palsy
- Down syndrome
- Impaired mobility
- Looked After Children

General Points

- The majority can be managed in primary care
- Can have a significant impact on health and wellbeing if not addressed and managed
- It is common and affects 5-30% of young children (most common in toddlers)
- It affects about 1% of adolescents
- Most are idiopathic
- 1 in 3 develop chronic symptoms
- Delays of >3d between stools may increase the likelihood of pain on passing hard stools leading to anal fissures, anal spasm and eventually a learned response to avoid defecation

Presenting Features

- Duration of symptoms and any 'trigger events'
- Stool pattern (<3 stools/wk may indicate constipation)
- Stool consistency (using Bristol stool chart) passage of firm or hard stools
- Faecal soiling the passage of liquid or formed stool into the child's underwear. This can be caused when stools have sat in the rectum for a long time.
- Straining or distress associated with opening bowels
- Poor appetite that resolves with opening of the bowels
- Abdominal pain that resolves with opening of the bowels
- Urinary symptoms (incontinence, UTI, retention)

Background History

- Passage of meconium within 48h of birth in a term baby
- Previous episodes of constipation or anal fissure
- Measures already tried
- Medications that may cause constipation (e.g. iron, opiates)
- · Diet and fluid intake
- Previous abdominal surgery
- Personal or family history of bowel disorders or connective tissue disorders (e.g. Ehler-Danlos, hypermobility)

Examination

- Check growth
- Abdominal examination
- Check lumbosacral spine for swelling, tuft of hair suggesting spinal dysraphism
- Lower limb neurological examination including tone, power and reflexes
- Visual inspection of perineum
- DO NOT perform a digital rectal examination

Differential Diagnoses

Although laxatives can be used safely in even very young infants, have a low threshold for discussing these patients with paediatrics. Particular considerations include;

- Cystic fibrosis (can occur even if Newborn Heel-Spot is normal)
- Thyroid disorders (can occur even if Newborn Heel Spot is normal)
- Hirschsprungs disease
 - Delayed passage of meconium (>48h in term babies)
 - o Constipation since first few weeks of life
 - o Chronic abdominal distension plus vomiting
 - Family history of Hirschsprungs disease
 - Faltering growth
- Bowel malformation
- Incorrectly made formula feeds
- Cow's milk protein allergy (constipation or loose stools)
- Medication (alginate antacids, Carobel, 'hungry baby formula', iron)

<u>Investigations</u>

Consider investigations if there is no response to optimum therapy within 3 months

- Bloods to look for causation: coeliac disease, thyroid function tests
- Bloods to consider if diet is poor: FBC, ferritin, vitamin D

Management

Do not use dietary interventions alone as first-line treatment

Diet

- Dietary interventions should be used alongside laxatives, rather than as first line treatment alone
- Increase fluid intake
- · High fibre foods

Behavioural

- Adapted to stage of development
- Include encouragement and reward systems
- Keep a bowel diary
- Scheduled toileting to establish a regular bowel habit utilise the gastro-colic reflex by visiting toilet after meals
 - Encourage child to sit on the toilet for 5-10 minutes
 - 20-30mins after breakfast
 - After lunch/when home from school
 - 20-30mins after dinner
 - Before bed
- Make toilet sitting fun blow bubbles, games that make them laugh
- Place child's feet on a step-stool, so their knees are above the hips, as this makes passing stool easier
- At least 60 mins of physical activity a day
- Massage the stomach in a clockwise direction

Medication

- Adjust dosages according to effect in order to establish a regular pattern of bowel movement in which stools are soft, well-formed and passed without discomfort
- Reassure about the safety of long-term laxative use
- The principle for medication in the treatment of constipation is a **high enough dose**, for a **long enough period**, which can be **gradually weaned down**.

First line laxative: oral macrogols, e.g. Laxido

Disimpaction Regime

Overflow soiling +/- palpable faecal mass are indications of impaction. If the child is impacted, a disimpaction regime should be commenced. If the child is not impacted, maintenance therapy should be commenced.

- The duration of treatment at the highest doses may vary and should be guided by response to treatment
- Disimpaction may initially increase symptoms of soiling and abdominal pain
- Disimpaction dose should be continued until there is a good response

PAEDIATRIC MACROGOLS						
Age: <1y*						
Sachets	1	2+				
Day	0.5-1	0.5-1				
Age: 1-4y						
Day	1	2	3	4	5	6+
Sachets	2	4	4	6	6	8
Age: 5-12y						
Day	1	2	3	4	5+	
Sachets	4	6	8	10	12	

ADULT MACROGOLS				
Age: 12-18y				
Day	1	2	3+	
Sachets	4	6	8	

^{*} Unlicensed dose

Maintenance Therapy

- It is useful to give a dose range for treatment so they can adjust medication within these limits over time
- Children who are toilet training should remain on laxatives until toilet training is well established
- Medication should not be stopped abruptly: reduce dose gradually over months in response to stool consistency and frequency
- Informed consent should be obtained and documented whenever medications/doses are prescribed that are different from those recommended by the BNFC.

Paediatric Macrogol

<1v: 0.5-1 sachet/d*

1-6y: 1 sachet/d (max 4/d) 6-12y: 2 sachets/d (max 4/d)

Adult Macrogol

12-18y: 1-3 sachets/d in divided doses; maintenance 1-2 sachets/d

Follow-up

- Child undergoing disimpaction regime: follow up to assess response within 1 week
- Child on maintenance regime: review response to treatment within 6 weeks and the dose titrated to produce a regular, soft stool
- If impaction recurs at any point during treatment, a disimpaction regime should be recommenced
- Maintenance therapy should be continued for several weeks after regular bowel habit is established
- No response by 3 months despite compliance with treatment reassess the patient for potential alternative diagnosis or complicating factors

Treatment Failure

The commonest reason for lack pf response is that they are not being administered correctly

^{*} Unlicensed dose

- Check understanding of number of sachets/d
- Space out doses across the day (solution stores well in fridge for 24h)
- Mix with cordial
- Mix with larger volume of liquid if texture not tolerated
- DO NOT mix with milk

Second Line

If oral macrogols are not effective but are being taken reliably: add stimulant laxative

If oral macrogols are not tolerated: use a stimulant but a softener (e.g. lactulose) will also be required

Stimulant laxatives					
Sodium picosulfate	1m-4y	2.5-10mg/d*			
5mg/5ml	4-18y	2.5-20mg/d*			
Bisocodyl 5mg tablets	4-18y	5-20mg/d*			
Senna	1m-4y	2.5-10ml/d			
7.5mg/5ml (not licensed <2y)	4-18y	2.5-20ml/d			
Senna 7.5mg tablets	2-4y	0.5-2 tablets/d			
	4-6y	0.4-4 tablets/d			
	6-18y	1-4 tablets/d			
Osmotic laxatives (softener)					
	1m-1y	2.5ml BD			
Lactulose	1-5y	2.5-10ml BD ⁺			
	5-18y	5-20ml BD*			
Stimulant with softening properties					
Sodium Docusate					
<12y paediatric oral solution	6m-2y	12.5mg TDS			
12.5ml/5ml	2-12y	12.5-25mg TDS			
>12y 100mg capsules	12-18y	Up to 500mg daily in divided doses			

^{*} Unlicensed dose

Referral Information

Indications for referral

- <1y who do not response to optimum therapy within 4 weeks URGENT referral consider Hirschsprungs
- Medical cause is suspected, e.g. dysmotility, suspected underlying primary bowel disorder, malabsorption
- Where optimum management has failed despite good compliance
- Complex cases, e.g. complex neurodisability, short gut
- Suspected Hirschsprungs disease
- Structural abnormality

[†] Non-BNFC recommended dose

Patient information leaflets/ PDAs

https://www.eric.org.uk/Pages/Category/bowel-problems https://www.thepoonurses.uk/

References

- National Institute for Clinical Excellence [NICE] (2017) Constipation in children and young people: diagnosis and management [Viewed 20 Aug 2021] https://www.nice.org.uk/guidance/cg99
- National Institute for Clinical Excellent [NICE] (2014) Constipation in children and young people: Quality Standard [Viewed 20 Aug 2021]
- https://www.nice.org.uk/guidance/qs62

Responsible GP: Dr Rebecca Brown Responsible Consultant: Dr Luke McLaughlin Responsible Pharmacist: Faisal Majothi

©NHS Vale of York Clinical Commissioning Group

Date published April 2022 Review date April 2027

The on-line version is the only version that is maintained. Any printed copies should, therefore, be viewed as 'uncontrolled' and as such may not necessarily contain the latest updates and amendments.